Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $20.85 billion. The enterprise value is $25.19 billion.
Market Cap | 20.85B |
Enterprise Value | 25.19B |
Important Dates
The next estimated earnings date is Wednesday, April 23, 2025, before market open.
Earnings Date | Apr 23, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Biogen has 146.37 million shares outstanding. The number of shares has increased by 0.21% in one year.
Current Share Class | 146.37M |
Shares Outstanding | 146.37M |
Shares Change (YoY) | +0.21% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.16% |
Owned by Institutions (%) | 91.16% |
Float | 146.00M |
Valuation Ratios
The trailing PE ratio is 12.74 and the forward PE ratio is 9.01. Biogen's PEG ratio is 2.62.
PE Ratio | 12.74 |
Forward PE | 9.01 |
PS Ratio | 2.14 |
Forward PS | 2.23 |
PB Ratio | 1.24 |
P/TBV Ratio | 38.19 |
P/FCF Ratio | 7.66 |
P/OCF Ratio | 7.25 |
PEG Ratio | 2.62 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.41, with an EV/FCF ratio of 9.25.
EV / Earnings | 15.43 |
EV / Sales | 2.60 |
EV / EBITDA | 8.41 |
EV / EBIT | 10.85 |
EV / FCF | 9.25 |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.40.
Current Ratio | 1.35 |
Quick Ratio | 0.77 |
Debt / Equity | 0.40 |
Debt / EBITDA | 2.15 |
Debt / FCF | 2.47 |
Interest Coverage | 9.28 |
Financial Efficiency
Return on equity (ROE) is 10.36% and return on invested capital (ROIC) is 6.36%.
Return on Equity (ROE) | 10.36% |
Return on Assets (ROA) | 5.29% |
Return on Invested Capital (ROIC) | 6.36% |
Return on Capital Employed (ROCE) | 10.31% |
Revenue Per Employee | $1.27M |
Profits Per Employee | $214,622 |
Employee Count | 7,605 |
Asset Turnover | 0.35 |
Inventory Turnover | 0.93 |
Taxes
In the past 12 months, Biogen has paid $273.80 million in taxes.
Income Tax | 273.80M |
Effective Tax Rate | 14.37% |
Stock Price Statistics
The stock price has decreased by -34.27% in the last 52 weeks. The beta is 0.01, so Biogen's price volatility has been lower than the market average.
Beta (5Y) | 0.01 |
52-Week Price Change | -34.27% |
50-Day Moving Average | 142.07 |
200-Day Moving Average | 178.77 |
Relative Strength Index (RSI) | 50.37 |
Average Volume (20 Days) | 1,814,527 |
Short Selling Information
The latest short interest is 3.88 million, so 2.65% of the outstanding shares have been sold short.
Short Interest | 3.88M |
Short Previous Month | 3.74M |
Short % of Shares Out | 2.65% |
Short % of Float | 2.66% |
Short Ratio (days to cover) | 1.85 |
Income Statement
In the last 12 months, Biogen had revenue of $9.68 billion and earned $1.63 billion in profits. Earnings per share was $11.18.
Revenue | 9.68B |
Gross Profit | 7.37B |
Operating Income | 2.32B |
Pretax Income | n/a |
Net Income | 1.63B |
EBITDA | 3.00B |
EBIT | 2.32B |
Earnings Per Share (EPS) | $11.18 |
Balance Sheet
The company has $2.38 billion in cash and $6.72 billion in debt, giving a net cash position of -$4.34 billion or -$29.66 per share.
Cash & Cash Equivalents | 2.38B |
Total Debt | 6.72B |
Net Cash | -4.34B |
Net Cash Per Share | -$29.66 |
Equity (Book Value) | 16.72B |
Book Value Per Share | 114.65 |
Working Capital | 1.93B |
Cash Flow
In the last 12 months, operating cash flow was $2.88 billion and capital expenditures -$153.70 million, giving a free cash flow of $2.72 billion.
Operating Cash Flow | 2.88B |
Capital Expenditures | -153.70M |
Free Cash Flow | 2.72B |
FCF Per Share | $18.59 |
Margins
Gross margin is 76.12%, with operating and profit margins of 24.00% and 16.87%.
Gross Margin | 76.12% |
Operating Margin | 24.00% |
Pretax Margin | 19.70% |
Profit Margin | 16.87% |
EBITDA Margin | 30.96% |
EBIT Margin | 24.00% |
FCF Margin | 28.13% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.21% |
Shareholder Yield | n/a |
Earnings Yield | 7.83% |
FCF Yield | 13.06% |
Analyst Forecast
The average price target for Biogen is $220.50, which is 54.81% higher than the current price. The consensus rating is "Buy".
Price Target | $220.50 |
Price Target Difference | 54.81% |
Analyst Consensus | Buy |
Analyst Count | 27 |
Revenue Growth Forecast (5Y) | 0.01% |
EPS Growth Forecast (5Y) | 10.15% |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
Last Split Date | Jan 18, 2001 |
Split Type | Forward |
Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 3.26 and a Piotroski F-Score of 6.
Altman Z-Score | 3.26 |
Piotroski F-Score | 6 |